Tharimmune, Inc. (THAR)

NASDAQ: THAR · IEX Real-Time Price · USD
4.574
+4.248 (1,306.80%)
At close: May 24, 2024, 4:00 PM
0.320
-4.254 (-93.00%)
After-hours: May 24, 2024, 7:49 PM EDT
1,306.80%
Market Cap 3.59M
Revenue (ttm) n/a
Net Income (ttm) -8.89M
Shares Out 11.79M
EPS (ttm) -2.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,029,787
Open 0.332
Previous Close 0.325
Day's Range 0.305 - 4.574
52-Week Range 0.301 - 10.875
Beta 1.66
Analysts n/a
Price Target n/a
Earnings Date May 9, 2024

About THAR

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minot... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 12, 2022
Employees 2
Stock Exchange NASDAQ
Ticker Symbol THAR
Full Company Profile

Financial Performance

Financial Statements

News

Tharimmune To Participate in Two Upcoming Investor Conferences in May

BRIDGEWATER, NJ / ACCESSWIRE / April 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates ...

27 days ago - Accesswire

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Obtained rights from Washington University to develop and incorporate human HER2 directed antibodies Complements early pipeline of novel tunable "Knob domain" antibodies for HER2 & HER3 BRIDGEWATER, N...

4 weeks ago - Accesswire

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April ...

Other symbols: OABI
6 weeks ago - Accesswire

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference BRIDGEWATER, NJ / ACCESS...

2 months ago - Accesswire

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studies Phase 1 clinical trial compared oral transmucosal delivery of TH...

3 months ago - Accesswire

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104 Phase 1 study expected to be completed in 1Q24 with topli...

4 months ago - Accesswire

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24 Planning well underway for Phase 2 of TH104 in primary biliary cholangiti...

4 months ago - Accesswire

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching intensity score after a single dose TH104 was well tolerated with no unexpe...

6 months ago - Accesswire

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

BRIDGEWATER, NJ / ACCESSWIRE / November 30, 2023 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...

6 months ago - Accesswire

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...

6 months ago - Accesswire

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability Company expects to engage FDA on Phase 2 trial design and expects topline...

6 months ago - Accesswire

Tharimmune Announces 1-for-25 Reverse Stock Split

BRIDGEWATER, NJ / ACCESSWIRE / November 17, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...

6 months ago - Accesswire

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Expects completion and topline data of a Phase 2 clinical trial in chronic pruritis over approximately 12 months after aligning with FDA on trial design Seeking first approval in an orphan disease, PB...

7 months ago - Accesswire

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstrea...

8 months ago - Accesswire

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months

9 months ago - GlobeNewsWire

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting dru...

9 months ago - GlobeNewsWire

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug...

10 months ago - GlobeNewsWire

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors

11 months ago - GlobeNewsWire

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3

11 months ago - GlobeNewsWire

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors

11 months ago - GlobeNewsWire

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

Appointment to Enhance Board's Expertise Across Investments, Business Development and Capital Markets Appointment to Enhance Board's Expertise Across Investments, Business Development and Capital Mark...

1 year ago - GlobeNewsWire

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) --  Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug...

1 year ago - GlobeNewsWire

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washin...

1 year ago - GlobeNewsWire

Hillstream BioPharma Announces Pricing of Public Offering

BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting dru...

1 year ago - GlobeNewsWire

Hillstream BioPharma Announces Proposed Public Offering

BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting dru...

1 year ago - GlobeNewsWire